PMID- 16164393
OWN - NLM
STAT- MEDLINE
DCOM- 20051230
LR  - 20220317
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 25
IP  - 9
DP  - 2005 Sep
TI  - Infections associated with tumor necrosis factor-alpha antagonists.
PG  - 1181-92
AB  - Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine involved in 
      a wide range of important physiologic processes. This cytokine has a pathologic 
      role in some diseases, and TNF-alpha antagonists are effective in treating 
      inflammatory conditions. Given the putative role of TNF-alpha in host defense 
      against tuberculosis and other infections, the risk of infection with TNF-alpha 
      antagonists is a concern. Therefore, we searched the literature for reports of 
      tuberculosis and other infections associated with TNF-alpha-antagonist therapy. 
      Although tuberculosis was rarely reported in randomized clinical comparisons of 
      these antagonists, case reports and submissions to the MedWatch program of the 
      United States Food and Drug Administration have been numerous. Most instances 
      were associated with infliximab, but etanercept and adalimumab may also be 
      associated with an increased risk of tuberculosis. Histoplasmosis, listeriosis, 
      aspergillosis, coccidioidomycosis, and candidiasis have been associated with 
      TNF-alpha antagonists, but the causative relationship is not clear. Potential 
      recipients of these drugs should be rigorously screened with skin testing, 
      detailed questioning about recent travel and potential tuberculosis exposure, 
      assessment for symptoms such as cough and weight loss, and chest radiography to 
      minimize their risk of acquiring or reactivating tuberculosis. As with other 
      immunosuppressant drugs, TNF-alpha antagonists should not be given to patients 
      with active infection.
FAU - Rychly, David J
AU  - Rychly DJ
AD  - College of Pharmacy, University of Georgia, Athens, Georgia, USA.
FAU - DiPiro, Joseph T
AU  - DiPiro JT
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adalimumab
MH  - Animals
MH  - Anti-Inflammatory Agents/adverse effects
MH  - Antibodies, Monoclonal/*adverse effects
MH  - Antibodies, Monoclonal, Humanized
MH  - Antirheumatic Agents/adverse effects
MH  - Etanercept
MH  - Gram-Positive Bacterial Infections/chemically induced
MH  - Humans
MH  - Immunoglobulin G/*adverse effects
MH  - Infliximab
MH  - Mycoses/chemically induced
MH  - Randomized Controlled Trials as Topic
MH  - Receptors, Tumor Necrosis Factor
MH  - Tuberculosis/*chemically induced
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
RF  - 200
EDAT- 2005/09/17 09:00
MHDA- 2005/12/31 09:00
CRDT- 2005/09/17 09:00
PHST- 2005/09/17 09:00 [pubmed]
PHST- 2005/12/31 09:00 [medline]
PHST- 2005/09/17 09:00 [entrez]
AID - 10.1592/phco.2005.25.9.1181 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2005 Sep;25(9):1181-92. doi: 10.1592/phco.2005.25.9.1181.